Completion of a significant clinical study

Completion of a significant clinical study - Axcellant

Completion of a significant clinical study

  1. Feb 01, 2024

Our team at Axcellant is proud to announce the completion of a significant Post-Market Clinical Follow-up study.

This study was meticulously designed to evaluate the performance and safety of a novel wound dressing technology in real-world settings. Emphasizing safety and performance, the study aimed to gather comprehensive data on the expected outcomes and to vigilantly monitor for any expected and unexpected adverse events. The study was completed ahead of schedule.

The success of this study is a testament to the collaborative effort of our dedicated team and the participating medical professionals, who navigated these challenges with expertise and commitment.

If you are interested in any type of medical devices study, please do not hesitate to contact us.

Resources

Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis

Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…

Axcellant to Attend EANM 2026 in Vienna

Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…